From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria
摘要:
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from. its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically, relevant Gram negative bacteria that is currently undergoing clinical trails.
[EN] NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND<br/>[FR] NOUVEAU COMPOSÉ HYDROXYPHÉNYLIQUE ANTIBACTÉRIEN
申请人:FAB PHARMA SAS
公开号:WO2011026529A1
公开(公告)日:2011-03-10
The invention relates to a novel hydroxyphenyl compound, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound.
Hydroxyphenyl Derivatives and Biological Applications Thereof
申请人:Denis Alexis
公开号:US20100041658A1
公开(公告)日:2010-02-18
The invention relates to hydroxyphenyl derivatives of formula (I); and uses thereof as anti-bacterial and/or anti-parasitic agents.
本发明涉及公式(I)的羟基苯基衍生物;以及其作为抗菌和/或抗寄生虫剂的用途。
NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND
申请人:Gerusz Vincent
公开号:US20120232155A1
公开(公告)日:2012-09-13
The invention relates to a novel hydroxyphenyl compound, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound.